{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T21:37:51Z","timestamp":1791236271220,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002386","name":"Cairo University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002386","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Nephrol"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The erythropoietin resistance index (ERI) is an accurate indicator of erythropoietin (EPO) resistance and is related to a worse prognosis in patients on hemodialysis (HD). ERI is simple, cheap and could be calculated easily in children receiving HD. We aimed to assess the EPO resistance in children with kidney failure on regular HD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An analytical cross-sectional study was conducted on 80 children with kidney failure on regular HD. They were assessed by history taking and laboratory investigations including complete blood count, C- reactive protein (CRP), iron, ferritin, parathyroid hormone and serum electrolytes. ERI was calculated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The study included 80 patients; 41 (51.2%) were male. The mean age of the study group was 8.86 \u00b1\u20092.76 years. Sixty-three patients (78.8%) were on iron therapy. Mean ERI was 28.87 \u00b1\u200910.62. The ERI was significantly positively correlated with age (r =\u20090.242;\n                      <jats:italic>P =\u2009<\/jats:italic>\n                      0.031), EPO dose (r =\u20090.290;\n                      <jats:italic>P =\u2009<\/jats:italic>\n                      0.001) and CRP (r =\u20090.219;\n                      <jats:italic>P =\u2009<\/jats:italic>\n                      0.049). The ERI had a significantly negative correlation with KT\/V (r =\u2009- 0.262;\n                      <jats:italic>P =\u2009<\/jats:italic>\n                      0.019), hemoglobin level (r =\u2009- 0.265;\n                      <jats:italic>P =\u2009<\/jats:italic>\n                      0.001) and platelet count (r =\u2009- 0.254;\n                      <jats:italic>P =\u2009<\/jats:italic>\n                      0.023).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Erythropoietin resistance is associated with many risk factors, including high CRP and low KT\/V. Inadequate HD is the most important risk factor for EPO resistance in children on chronic HD. Adequate HD is considered as a protective measure against EPO resistance.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphical Abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1007\/s00467-025-06776-4","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T08:49:00Z","timestamp":1745830140000},"page":"3725-3732","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Erythropoietin resistance among pediatric patients on chronic hemodialysis: A cross-sectional study"],"prefix":"10.1007","volume":"40","author":[{"given":"Rasha","family":"Helmy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatina I.","family":"Fadel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha E.","family":"Galal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amira M.","family":"Mohammed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9009-165X","authenticated-orcid":false,"given":"Shaimaa","family":"Sayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"key":"6776_CR1","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1182\/blood-2018-06-856500","volume":"133","author":"G Weiss","year":"2019","unstructured":"Weiss G, Ganz T, Goodnough LT (2019) Anemia of inflammation. Blood 133:40\u201350","journal-title":"Blood"},{"key":"6776_CR2","doi-asserted-by":"publisher","first-page":"642296","DOI":"10.3389\/fmed.2021.642296","volume":"8","author":"J Portoles","year":"2021","unstructured":"Portoles J, Martin L, Broseta JJ, Cases A (2021) Anemia in chronic kidney disease: from pathophysiology and current treatments to future agents. Front Med 8:642296","journal-title":"Front Med"},{"key":"6776_CR3","first-page":"692","volume":"32","author":"K Birnie","year":"2017","unstructured":"Birnie K, Caskey F, Ben-Shlomo Y, Sterne JA, Gilg J, Nitsch D et al (2017) Erythropoiesis-stimulating agent dosing, haemoglobin and ferritin levels in UK haemodialysis patients 2005\u201313. Nephrol Dial Transplant 32:692\u2013698","journal-title":"Nephrol Dial Transplant"},{"key":"6776_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.12928\/admj.v1i2.3131","volume":"1","author":"RGP Putri","year":"2020","unstructured":"Putri RGP, Sholihah A, Sukirto NW (2020) Risk factor for erythropoietin resistance in hemodialysis patient: literature review. Ahmad Dahlan Med J 1:33\u201349","journal-title":"Ahmad Dahlan Med J"},{"key":"6776_CR5","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1111\/1744-9987.12380","volume":"20","author":"DG Taymez","year":"2016","unstructured":"Taymez DG, Ucar E, Turkmen K, Ucar R, Afsar B, Gaipov A et al (2016) The predictive value of platelet\/lymphocyte ratio in hemodialysis patients with erythropoietin resistance. Ther Apher Dial 20:118\u2013121","journal-title":"Ther Apher Dial"},{"key":"6776_CR6","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s40620-014-0121-9","volume":"28","author":"R Eriguchi","year":"2015","unstructured":"Eriguchi R, Taniguchi M, Ninomiya T, Hirakata H, Fujimi S, Tsuruya K et al (2015) Hyporesponsiveness to erythropoiesis-stimulating agent as a prognostic factor in Japanese hemodialysis patients: the Q-Cohort study. J Nephrol 28:217\u2013225","journal-title":"J Nephrol"},{"key":"6776_CR7","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1159\/000516901","volume":"52","author":"MR Weir","year":"2021","unstructured":"Weir MR (2021) Managing anemia across the stages of kidney disease in those hyporesponsive to erythropoiesis-stimulating agents. Am J Nephrol 52:450\u2013466","journal-title":"Am J Nephrol"},{"key":"6776_CR8","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1038\/kisup.2012.37","volume":"2","author":"J McMurray","year":"2012","unstructured":"McMurray J, Parfrey P, Adamson JW, Aljama P, Berns JS, Bohlius J et al (2012) Kidney disease: Improving global outcomes (KDIGO) anemia work group. KDIGO clinical practice guideline for anemia in chronic kidney disease. Kidney Int Suppl 2:279\u2013333","journal-title":"Kidney Int Suppl"},{"key":"6776_CR9","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000346740","volume":"122","author":"T Fujikawa","year":"2012","unstructured":"Fujikawa T, Ikeda Y, Fukuhara S et al (2012) Time-dependent resistance to erythropoiesis-stimulating agent and mortality in hemodialysis patients in the Japan dialysis outcomes and practice patterns study. Nephron Clin Pract 122:24\u201332","journal-title":"Nephron Clin Pract"},{"key":"6776_CR10","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1159\/000519644","volume":"51","author":"J Zhang","year":"2022","unstructured":"Zhang J, Lu X, Wang S, Li H (2022) Neutrophil-to-lymphocyte ratio and erythropoietin resistance among maintenance hemodialysis patients. Blood Purif 51:708\u2013713","journal-title":"Blood Purif"},{"key":"6776_CR11","doi-asserted-by":"publisher","first-page":"205435811773556","DOI":"10.1177\/2054358117735563","volume":"4","author":"J Pineault","year":"2017","unstructured":"Pineault J, Lamarche C, Bell R, Lafrance JP, Ouellet G, Leblanc M et al (2017) Association of neutrophil-to-lymphocyte ratio with inflammation and erythropoietin resistance in chronic dialysis patients. Can J Kidney Health Dis 4:2054358117735563","journal-title":"Can J Kidney Health Dis"},{"key":"6776_CR12","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.nefro.2015.10.018","volume":"36","author":"D Mart\u00ednez-Urbistondo","year":"2016","unstructured":"Mart\u00ednez-Urbistondo D, Beltr\u00e1n A, Beloqui O, Huerta A (2016) The neutrophil\u2013lymphocyte ratio as a marker of systemic endothelial dysfunction in asymptomatic subjects. Nefrologia 36:397\u2013403","journal-title":"Nefrologia"},{"key":"6776_CR13","doi-asserted-by":"publisher","DOI":"10.1177\/00099228241299893","author":"M Kaya","year":"2024","unstructured":"Kaya M, Cicek N, Guven S, Alpay H, Gokce I (2024) Resistance to erythropoiesis stimulating agents in children receiving renal replacement therapy. Clin Pediatr (Phila). https:\/\/doi.org\/10.1177\/00099228241299893","journal-title":"Clin Pediatr (Phila)"},{"key":"6776_CR14","unstructured":"Brooks A (2024) Erythropoietin resistance increases risk of mortality in patients with anemia, CKD. https:\/\/www.hcplive.com\/view\/erythropoietin-resistance-increases-risk-mortality-patients-with-anemia-ckd. Accessed 10 March 2025"},{"key":"6776_CR15","first-page":"55","volume":"45","author":"YH Chan","year":"2004","unstructured":"Chan YH (2004) Biostatistics 201: linear regression analysis. Singapore Med J 45:55\u201361","journal-title":"Singapore Med J"},{"key":"6776_CR16","doi-asserted-by":"publisher","first-page":"s55","DOI":"10.1590\/1806-9282.66.s1.55","volume":"66","author":"MAA Hazin","year":"2020","unstructured":"Hazin MAA (2020) Anemia in chronic kidney disease. Rev Assoc Med Bras 66:s55\u2013s58","journal-title":"Rev Assoc Med Bras"},{"issue":"Suppl 69","key":"6776_CR17","first-page":"20","volume":"34","author":"RF Rivera","year":"2017","unstructured":"Rivera RF, Alibrandi MTS, Di Lullo L, Fioccari F (2017) Clinical management of anemia in patients with CKD. G Ital Nefrol 34(Suppl 69):20\u201335","journal-title":"G Ital Nefrol"},{"key":"6776_CR18","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1007\/s00467-008-0954-3","volume":"24","author":"OF Bamgbola","year":"2009","unstructured":"Bamgbola OF, Fredrick J, Kaskel FJ, Coco M (2009) Analyses of age, gender and other risk factors of erythropoietin resistance in pediatric and adult dialysis cohorts. Pediatr Nephrol 24:571\u2013579","journal-title":"Pediatr Nephrol"},{"key":"6776_CR19","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1159\/000514060","volume":"50","author":"AS P\u0131narba\u015f\u0131","year":"2021","unstructured":"P\u0131narba\u015f\u0131 AS, Dursun I, G\u00fcnay N, Baatar B, Yel S, Dursun J et al (2021) Erythropoietin resistance index and the affecting factors in children with peritoneal dialysis. Blood Purif 50:942\u2013951","journal-title":"Blood Purif"},{"key":"6776_CR20","first-page":"697","volume":"16","author":"F Coronel","year":"2003","unstructured":"Coronel F, Herrero JA, Montenegro J, Fernandez C, Gandara A, Conesa J et al (2003) Erythropoietin requirements: a comparative multicenter study between peritoneal dialysis and hemodialysis. J Nephrol 16:697\u2013707","journal-title":"J Nephrol"},{"key":"6776_CR21","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1159\/000335685","volume":"35","author":"U Duong","year":"2012","unstructured":"Duong U, Kalantar-Zadeh K, Molnar MZ et al (2012) Mortality associated with dose response of erythropoiesis-stimulating agents in hemodialysis versus peritoneal dialysis patients. Am J Nephrol 35:198\u2013208","journal-title":"Am J Nephrol"},{"key":"6776_CR22","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1046\/j.1523-1755.61.s80.11.x","volume":"80","author":"IC Macdougall","year":"2002","unstructured":"Macdougall IC (2002) Darbepoetin alfa: a new therapeutic agent for renal anemia. Kidney Int Suppl 80:55\u201361","journal-title":"Kidney Int Suppl"},{"key":"6776_CR23","first-page":"353","volume":"7","author":"J Arrieta","year":"2014","unstructured":"Arrieta J, Moina I, Molina J et al (2014) Switch from epoetin to darbepoetin alfa in hemodialysis: dose equivalence and hemoglobin stability. Int J Nephrol Renovasc Dis 7:353\u2013359","journal-title":"Int J Nephrol Renovasc Dis"},{"key":"6776_CR24","doi-asserted-by":"publisher","first-page":"e04","DOI":"10.34172\/jre.2021.04","volume":"7","author":"A Osman","year":"2021","unstructured":"Osman A, Alkareem NA, EldinElawad B, Dawod O, Elshiekh M (2021) Impact of gender, C-reactive protein and body mass index on erythropoietin resistance index in maintenance hemodialysis patients. J Renal Endocrin 7:e04","journal-title":"J Renal Endocrin"},{"key":"6776_CR25","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1111\/j.1542-4758.2011.00644.x","volume":"16","author":"S Chung","year":"2012","unstructured":"Chung S, Song HC, Shin SJ, Ihm SH, Park CS, Kim HY et al (2012) Relationship between erythropoietin resistance index and left ventricular mass and function and cardiovascular events in patients on chronic hemodialysis. Hemodial Int 16:181\u2013187","journal-title":"Hemodial Int"},{"key":"6776_CR26","doi-asserted-by":"crossref","unstructured":"Ingrasciotta Y, Lacava V, Marcian\u00f2 I, Giorgianni F, Tripepi G, D\u2019Arrigo G et al (2019) In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study. BMC Nephrol 20:359","DOI":"10.1186\/s12882-019-1554-0"},{"key":"6776_CR27","doi-asserted-by":"publisher","first-page":"197","DOI":"10.5507\/bp.2013.093","volume":"159","author":"J Zadrazil","year":"2015","unstructured":"Zadrazil J, Horak P (2015) Pathophysiology of anemia in chronic kidney diseases: a review. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 159:197\u2013202","journal-title":"Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub"},{"key":"6776_CR28","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1159\/000358215","volume":"37","author":"M Okazaki","year":"2014","unstructured":"Okazaki M, Komatsu M, Kawaguchi H, Tsuchiya K, Nitta K (2014) Erythropoietin resistance index and the all-cause mortality of chronic hemodialysis patients. Blood Purif 37:106\u2013112","journal-title":"Blood Purif"},{"key":"6776_CR29","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s11255-016-1499-1","volume":"49","author":"A Ryta","year":"2017","unstructured":"Ryta A, Chmielewski M, Debska-Slizien A, Jagodzinski P, Sikorska-Wisniewska M, Lichodziejewska-Niemierko M (2017) Impact of gender and dialysis adequacy on anaemia in peritoneal dialysis. Int Urol Nephrol 49:903\u2013908","journal-title":"Int Urol Nephrol"},{"key":"6776_CR30","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.nefro.2019.09.007","volume":"40","author":"F Valga","year":"2020","unstructured":"Valga F, Monz\u00f3n T, Henriquez F, Santana-del-Pino A, Ant\u00f3n-P\u00e9rez G (2020) Platelet-to-lymphocyte and neutrophil-to-lymphocyte ratios as markers of erythropoietin resistance in chronic haemodialysis patients: a multicentre cross-sectional study. Nefrologia 40:320\u2013327","journal-title":"Nefrologia"},{"key":"6776_CR31","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1111\/hdi.12407","volume":"20","author":"Y Chait","year":"2016","unstructured":"Chait Y, Kalim S, Horowitz J, Hollot CV, Ankers ED, Germain MJ et al (2016) The greatly misunderstood erythropoietin resistance index and the case for a new responsiveness measure. Hemodial Int 20:392\u2013398","journal-title":"Hemodial Int"},{"key":"6776_CR32","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1016\/j.pbj.2017.07.053","volume":"2","author":"S R\u0117kut\u0117","year":"2017","unstructured":"R\u0117kut\u0117 S (2017) Influence of blood inflammatory parameters to erythropoietin resistance in haemodialysis patients. Porto Biomed J 2:176\u2013246","journal-title":"Porto Biomed J"},{"key":"6776_CR33","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1159\/000438870","volume":"131","author":"M Kimachi","year":"2015","unstructured":"Kimachi M, Fukuma S, Yamazaki S, Yamamoto Y, Akizawa T, Akiba T et al (2015) Minor elevation in C-reactive protein levels predicts incidence of erythropoiesis-stimulating agent hyporesponsiveness among hemodialysis patients. Nephron 131:123\u2013130","journal-title":"Nephron"},{"key":"6776_CR34","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1111\/j.1440-1797.2007.00810.x","volume":"12","author":"DW Johnson","year":"2007","unstructured":"Johnson DW, Pollock CA, Macdougall IC (2007) Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology 12:321\u2013330","journal-title":"Nephrology"},{"key":"6776_CR35","doi-asserted-by":"publisher","first-page":"9598211","DOI":"10.1155\/2022\/9598211","volume":"2022","author":"J JoksimovicJovic","year":"2022","unstructured":"JoksimovicJovic J, Antic S, Nikolic T, Andric K, Petrovic D, Bolevich S et al (2022) Erythropoietin resistance development in hemodialysis patients: the role of oxidative stress. Oxid Med Cell Longev 2022:9598211","journal-title":"Oxid Med Cell Longev"},{"key":"6776_CR36","doi-asserted-by":"publisher","first-page":"1027230","DOI":"10.1155\/2020\/1027230","volume":"2020","author":"X Lu","year":"2020","unstructured":"Lu X, Zhang J, Wang S, Yu Q, Li H (2020) High erythropoiesis resistance index is a significant predictor of cardiovascular and all-cause mortality in Chinese maintenance hemodialysis patients. Mediators Inflamm 2020:1027230","journal-title":"Mediators Inflamm"},{"key":"6776_CR37","doi-asserted-by":"publisher","first-page":"70","DOI":"10.3109\/0886022X.2015.1104990","volume":"38","author":"BL Neuen","year":"2016","unstructured":"Neuen BL, Leather N, Greenwood AM, Gunnarsson R, Cho Y, Mantha ML (2016) Neutrophil\u2013lymphocyte ratio predicts cardiovascular and all-cause mortality in hemodialysis patients. Ren Fail 38:70\u201376","journal-title":"Ren Fail"},{"key":"6776_CR38","doi-asserted-by":"publisher","first-page":"174","DOI":"10.5414\/CN109403","volume":"92","author":"A Maeda","year":"2019","unstructured":"Maeda A, Tsuruya K, Maeda M, Yamasaki M, Nakashima A, Nakashima Y et al (2019) Hemodialysis treatment time versus erythropoietin dose requirement: Reduction in 2,000 units per week by extension of hemodialysis for 1 hour. Clin Nephrol 92:174\u2013179","journal-title":"Clin Nephrol"}],"container-title":["Pediatric Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06776-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00467-025-06776-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00467-025-06776-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T09:24:41Z","timestamp":1761211481000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00467-025-06776-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":38,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["6776"],"URL":"https:\/\/doi.org\/10.1007\/s00467-025-06776-4","relation":{},"ISSN":["0931-041X","1432-198X"],"issn-type":[{"value":"0931-041X","type":"print"},{"value":"1432-198X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"28 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been approved by the Research Ethics Committee, Faculty of Medicine, Cairo University (approval code: MS- 95\u20132022). Written informed consent was obtained from the parents or legal guardians of the children.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}